MD Anderson acquires inducible switch technologies for cell therapy
The University of Texas MD Anderson Cancer Center today announced it has acquired certain assets from Bellicum Pharmaceuticals, Inc. related to the CaspaCIDe® switch platform and the GoCAR® platform. The transaction also includes clinical-grade stocks of rimiducid, an agent used to trigger the switches.
As a result of this acquisition, MD Anderson may incorporate these platforms into its own cell therapy...
MD Anderson and C-Biomex sign collaborative research agreement to co-develop CBT-001 radioligand therapy
The University of Texas MD Anderson Cancer Center and C-Biomex Ltd. today announced a strategic research collaboration agreement to co-develop...